Eliciting protective T cell immunity against EBV-associated malignancies by vaccination

      Background: Epstein-Barr virus (EBV) is a γ-herpesvirus that preferentially infects B cells and establishes life-long chronic infection in more than 90% of the adult human population worldwide. The virus-host balance is mainly sustained by T-cell responses, which are able to control the infection asymptomatically. However, when T-cell immune control fails, EBV is associated with a number of human malignancies such as Burkitt’s lymphoma, Hodgkin’s lymphoma and nasopharyngeal carcinoma. Existing vaccine strategies against EBV have not proven to be sufficient to combat EBV-associated tumors. Therefore, this project aims to develop new EBV vaccine candidates to prevent and to treat EBV-associated malignancies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect